Clinical Trial Update: ALX-0171 Safety Study in Adults With Hyperresponsive Airways [Phase 1]

View source ↗

Summary

Phase 1 safety study of ALX-0171 in adults with hyperresponsive airways infected with respiratory syncytial virus, conducted by Ablynx (a Sanofi company); the t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• ALX-0171

Snippet

Sponsor: Ablynx, a Sanofi company | Conditions: Respiratory Syncytial Virus Infection | Phase 1 | Status: COMPLETED